Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety roll-over study of asciminib in CML
2021-000602-17Phase 3Active
- Sponsor
- Novartis
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Frequency and severity of adverse events and serious adverse events. Started Jun 2021; status: active.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2021-000602-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000602-17.